Microwave ablation of 105 T1 renal tumors: technique efficacy with a mean follow-up of two years

• Published in: Acta radiologica (1987) Vol. 65; no. 3; pp. 294 - 301
• Main Authors: Acosta Ruiz, Vanessa, Dahlman, Pär, Brekkan, Einar, Lönnemark, Maria, Magnusson, Anders
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.03.2024
• Subjects: Aged; Catheter Ablation - methods; Follow-Up Studies; Humans; Kidney Neoplasms - diagnostic imaging; Kidney Neoplasms - surgery; Microwaves - therapeutic use; Retrospective Studies; Treatment Outcome; computed tomography; kidney; percutaneous; Ablation procedures
• ISSN: 0284-1851; 1600-0455
• DOI: 10.1177/0284185120956283

Background Thermal ablation (TA) with radiofrequency (RFA) or cryoablation (CA) are established treatments for small renal masses (≤4 cm). Microwave ablation (MWA) has several potential benefits (decreased ablation time, less susceptibility to heat-sink, higher lesion temperatures than RFA) but is still considered experimental considering the available small-sample studies with short follow-up. Purpose To evaluate technique efficacy and complications of our initial experience of renal tumors treated using percutaneous MWA with a curative intent. Material and Methods A total of 105 renal tumors (in 93 patients) were treated between April 2014 and August 2017. MWA was performed percutaneously with computed tomography (CT) guidance under conscious sedation (n=82) or full anesthesia. Patients were followed with contrast-enhanced CT scans at six months and yearly thereafter for a minimum of five years. The mean follow-up time was 2.1 years. The percentage of tumors completely ablated in a single session (primary efficacy rate) and those successfully treated after repeat ablation (secondary efficacy rate) were recorded. Patient and tumor characteristics as well as complications were collected retrospectively. Results The median patient age was 70 years and median tumor size was 25 mm. Primary efficacy rate was 96.2% (101/105 tumors). After including two residual tumors for a second ablation session, secondary efficacy was 97.1% (102/105). Periprocedural complications were found in 5.2% (5/95) sessions: four Clavien-Dindo I and one Clavien-Dindo IIIa. One postprocedural Clavien-Dindo II complication was found. Conclusion MWA has high efficacy rates and few complications compared to other TA methods at a mean follow-up of two years.